TY - JOUR
T1 - Assessment of ICD eligibility in non-ischaemic cardiomyopathy patients
T2 - a position statement by the Task Force of the Dutch Society of Cardiology
AU - van der Lingen, Anne-Lotte C. J.
AU - Verstraelen, Tom E.
AU - van Erven, Lieselot
AU - Meeder, Joan G.
AU - Theuns, Dominic A.
AU - Vernooy, Kevin
AU - Wilde, Arthur A. M.
AU - Maass, Alexander H.
AU - Allaart, Cornelis P.
N1 - Publisher Copyright: © The Author(s) 2024.
PY - 2024/5/1
Y1 - 2024/5/1
N2 - International guidelines recommend implantation of an implantable cardioverter-defibrillator (ICD) in non-ischaemic cardiomyopathy (NICM) patients with a left ventricular ejection fraction (LVEF) below 35% despite optimal medical therapy and a life expectancy of more than 1 year with good functional status. We propose refinement of these recommendations in patients with NICM, with careful consideration of additional risk parameters for both arrhythmic and non-arrhythmic death. These additional parameters include late gadolinium enhancement on cardiac magnetic resonance imaging and genetic testing for high-risk genetic variants to further assess arrhythmic risk, and age, comorbidities and sex for assessment of non-arrhythmic mortality risk. Moreover, several risk modifiers should be taken into account, such as concomitant arrhythmias that may affect LVEF (atrial fibrillation, premature ventricular beats) and resynchronisation therapy. Even though currently no valid cut-off values have been established, the proposed approach provides a more careful consideration of risks that may result in withholding ICD implantation in patients with low arrhythmic risk and substantial non-arrhythmic mortality risk.
AB - International guidelines recommend implantation of an implantable cardioverter-defibrillator (ICD) in non-ischaemic cardiomyopathy (NICM) patients with a left ventricular ejection fraction (LVEF) below 35% despite optimal medical therapy and a life expectancy of more than 1 year with good functional status. We propose refinement of these recommendations in patients with NICM, with careful consideration of additional risk parameters for both arrhythmic and non-arrhythmic death. These additional parameters include late gadolinium enhancement on cardiac magnetic resonance imaging and genetic testing for high-risk genetic variants to further assess arrhythmic risk, and age, comorbidities and sex for assessment of non-arrhythmic mortality risk. Moreover, several risk modifiers should be taken into account, such as concomitant arrhythmias that may affect LVEF (atrial fibrillation, premature ventricular beats) and resynchronisation therapy. Even though currently no valid cut-off values have been established, the proposed approach provides a more careful consideration of risks that may result in withholding ICD implantation in patients with low arrhythmic risk and substantial non-arrhythmic mortality risk.
KW - Implantable cardioverter defibrillator
KW - Mortality
KW - Non-ischaemic cardiomyopathy
KW - Sudden cardiac death
UR - http://www.scopus.com/inward/record.url?scp=85190815661&partnerID=8YFLogxK
U2 - 10.1007/s12471-024-01859-7
DO - 10.1007/s12471-024-01859-7
M3 - Article
C2 - 38634993
SN - 1568-5888
VL - 32
SP - 190
EP - 197
JO - Netherlands heart journal
JF - Netherlands heart journal
IS - 5
ER -